Shire bags a quick thumbs up for its newly won cancer drug pipeline
Shire is ready to cash in its first cancer drug chip won in its acquisition of Baxalta.
The biotech company says that the EMA’s Committee for Medicinal Products for Human Use has given it a thumbs up on an application to market Onivyde — an irinotecan liposome injection combined with 5-fluorouracil and leucovorin to fight metastatic pancreatic cancer as a second-line drug after gemcitabine therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.